Diagnostic Histopathology
Volume 15, Issue 2 , Pages 79-86 , February 2009

Familial disorders of the parathyroid gland

References 

  1. Marx SJ, Agarwal SK, Kester MB, et al. Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res. 1999;54:397–438discussion 438–9
  2. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658–5671
  3. Shen HC, Rosen JE, Yang LM, et al. Parathyroid tumor development involves deregulation of homeobox genes. Endocr Relat Cancer. 2008;15:267–275
  4. Agarwal SK, Lee Burns A, Sukhodolets KE, et al. Molecular pathology of the MEN1 gene. Ann N Y Acad Sci. 2004;1014:189–198
  5. Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat. 2008;29:22–32
  6. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. Mol Endocrinol. 2001;15:1653–1664
  7. Klein RD, Salih S, Bessoni J, Bale AE. Clinical testing for multiple endocrine neoplasia type 1 in a DNA diagnostic laboratory. Genet Med. 2005;7:131–138
  8. Ellard S, Hattersley AT, Brewer CM, Vaidya B. Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf). 2005;62:169–175
  9. Scarpelli D, D’Aloiso L, Arturi F, et al. Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics. J Endocrinol Invest. 2004;27:1015–1021
  10. Haven CJ, Howell VM, Eilers PH, et al. Gene expression of parathyroid tumors: molecular subclassification and identification of the potential malignant phenotype. Cancer Res. 2004;64:7405–7411
  11. Haven CJ, van Puijenbroek M, Tan MH, et al. Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin Endocrinol (Oxf). 2007;67:370–376
  12. Arnold A, Shattuck TM, Mallya SM, et al. Molecular pathogenesis of primary hyperparathyroidism. J Bone Miner Res. 2002;17(Suppl. 2):N30–N36
  13. Erickson LA, Jalal SM, Harwood A, Shearer B, Jin L, Lloyd RV. Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization. Am J Surg Pathol. 2004;28:578–584
  14. Hsi ED, Zukerberg LR, Yang WI, Arnold A. Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab. 1996;81:1736–1739
  15. Oishi S, Sato T, Takiguchi-Shirahama S, Nakamura Y. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple’s syndrome). Endocr J. 1995;42:527–536
  16. Machens A, Dralle H. Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma. World J Surg. 2007;31:957–968
  17. Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc. 1996;276:1575–1579
  18. Kimura T, Yoshimoto K, Tanaka C, et al. Obvious mRNA and protein expression but absence of mutations of the RET proto-oncogene in parathyroid tumors. Eur J Endocrinol. 1996;134:314–319
  19. Aida K, Koishi S, Tawata M, Onaya T. Molecular cloning of a putative Ca(2+)-sensing receptor cDNA from human kidney. Biochem Biophys Res Commun. 1995;214:524–529
  20. Kifor O, Moore FD, Delaney M, et al. A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J Clin Endocrinol Metab. 2003;88:60–72
  21. Aida K, Koishi S, Inoue M, Nakazato M, Tawata M, Onaya T. Familial hypocalciuric hypercalcemia associated with mutation in the human Ca(2+)-sensing receptor gene. J Clin Endocrinol Metab. 1995;80:2594–2598
  22. Pearce SH, Williamson C, Kifor O, et al. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N Engl J Med. 1996;335:1115–1122
  23. Janicic N, Soliman E, Pausova Z, et al. Mapping of the calcium-sensing receptor gene (CASR) to human chromosome 3q13.3-21 by fluorescence in situ hybridization, and localization to rat chromosome 11 and mouse chromosome 16. Mamm Genome. 1995;6:798–801
  24. Cole DE, Janicic N, Salisbury SR, Hendy GN. Neonatal severe hyperparathyroidism, secondary hyperparathyroidism, and familial hypocalciuric hypercalcemia: multiple different phenotypes associated with an inactivating Alu insertion mutation of the calcium-sensing receptor gene. Am J Med Genet. 1997;71:202–210
  25. Hauache OM. Extracellular calcium-sensing receptor: structural and functional features and association with diseases. Braz J Med Biol Res. 2001;34:577–584
  26. Hellman P, Carling T, Rask L, Akerstrom G. Pathophysiology of primary hyperparathyroidism. Histol Histopathol. 2000;15:619–627
  27. De Luca F, Baron J. Molecular biology and clinical importance of the Ca(2+)-sensing receptor. Curr Opin Pediatr. 1998;10:435–440
  28. Rodriguez Soriano J. Neonatal hypercalcemia. J Nephrol. 2003;16:606–608
  29. Hosokawa Y, Pollak MR, Brown EM, Arnold A. Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. J Clin Endocrinol Metab. 1995;80:3107–3110
  30. Thompson DB, Samowitz WS, Odelberg S, Davis RK, Szabo J, Heath H. Genetic abnormalities in sporadic parathyroid adenomas: loss of heterozygosity for chromosome 3q markers flanking the calcium receptor locus. J Clin Endocrinol Metab. 1995;80:3377–3380
  31. Warner JV, Nyholt DR, Busfield F, et al. Familial isolated hyperparathyroidism is linked to a 1.7 Mb region on chromosome 2p13.3-14. J Med Genet. 2006;43:e12
  32. Wassif WS, Moniz CF, Friedman E, et al. Familial isolated hyperparathyroidism: a distinct genetic entity with an increased risk of parathyroid cancer. J Clin Endocrinol Metab. 1993;77:1485–1489
  33. Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD, Marx SJ. Familial isolated hyperparathyroidism is rarely caused by germline mutation in HRPT2, the gene for the hyperparathyroidism-jaw tumor syndrome. J Clin Endocrinol Metab. 2004;89:96–102
  34. Marx SJ. Hyperparathyroid and hypoparathyroid disorders. N Engl J Med. 2000;343:1863–1875
  35. Cetani F, Pardi E, Borsari S, et al. Genetic analyses of the HRPT2 gene in primary hyperparathyroidism: germline and somatic mutations in familial and sporadic parathyroid tumors. J Clin Endocrinol Metab. 2004;89:5583–5591
  36. Carpten JD, Robbins CM, Villablanca A, et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat Genet. 2002;32:676–680
  37. Szabo J, Heath B, Hill VM, et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21–q31. Am J Hum Genet. 1995;56:944–950
  38. Bondeson L, Grimelius L, DeLellis RA, et al. Parathyroid carcinoma. In:  DeLellis RA,  Lloyd RV,  Heitz PU,  Eng C editor. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004;p. 124–132
  39. Erickson LA, Jin L, Wollan P, Thompson GB, van Heerden JA, Lloyd RV. Parathyroid hyperplasia, adenomas, and carcinomas: differential expression of p27Kip1 protein. Am J Surg Pathol. 1999;23:288–295
  40. Alwaheeb S, Rambaldini G, Boerner S, Coire C, Fiser J, Asa SL. Worrisome histologic alterations following fine-needle aspiration of the parathyroid. J Clin Pathol. 2006;59:1094–1096
  41. Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722–1729
  42. Krebs LJ, Shattuck TM, Arnold A. HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J Clin Endocrinol Metab. 2005;90:5015–5017
  43. Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629–6637
  44. Gill AJ, Clarkson A, Gimm O, et al. Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am J Surg Pathol. 2006;30:1140–1149
  45. Tominaga Y, Tsuzuki T, Matsuoka S, et al. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease. World J Surg. 2008;32:815–821
  46. Juhlin C, Larsson C, Yakoleva T, et al. Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr Relat Cancer. 2006;13:509–523
  47. Cryns VL, Rubio MP, Thor AD, Louis DN, Arnold A. p53 abnormalities in human parathyroid carcinoma. J Clin Endocrinol Metab. 1994;78:1320–1324
  48. Cryns VL, Thor A, Xu HJ, et al. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma. N Engl J Med. 1994;330:757–761
  49. Yagi H, Furutani Y, Hamada H, et al. Role of TBX1 in human del22q11.2 syndrome. Lancet. 2003;362:1366–1373
  50. Parvari R, Hershkovitz E, Grossman N, et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet. 2002;32:448–452
  51. Schumann C, Faust M, Gerharz M, Ortmann M, Schubert M, Krone W. Autoimmune polyglandular syndrome associated with idiopathic giant cell myocarditis. Exp Clin Endocrinol Diabetes. 2005;113:302–307
  52. Goswami R, Brown EM, Kochupillai N, et al. Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur J Endocrinol. 2004;150:9–18

PII: S1756-2317(09)00004-8

doi: 10.1016/j.mpdhp.2009.01.001

Diagnostic Histopathology
Volume 15, Issue 2 , Pages 79-86 , February 2009

Article Tools

* Image Usage & Resolution